We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

GE Healthcare

GE Healthcare provides medical imaging and information technologies, medical diagnostics, patient monitoring systems,... read more Featured Products: More products

Download Mobile App

World’s First Image Analysis System Predicts and Visualizes 24-Hour Post-Treatment Ablation Morphology in Real-Time

By MedImaging International staff writers
Posted on 03 Jul 2023
Print article
Image: The BioTrace.IO - AI-based image guided ablation therapy platform (Photo courtesy of Techsomed)
Image: The BioTrace.IO - AI-based image guided ablation therapy platform (Photo courtesy of Techsomed)

Thermal ablation, a minimally invasive treatment for liver tumors, has been unable to achieve its full potential due to limited visualization during the procedure. This limitation creates a significant discrepancy between the intended treatment and actual results, potentially leading to unnecessary patient risks. These risks can include damage to healthy tissue or insufficient destruction of tumor cells, contributing to local tumor recurrence rates. Now, an AI-powered software platform for real-time ablation zone imaging and treatment precision enhancement marks a significant advancement in image-guided ablation therapy.

Techsomed Ltd.’s (Rehovot, Israel) BioTraceIO360 software, currently in advanced clinical evaluation, is the world’s first and only image analysis system that can predict and visualize the morphology of the ablation site 24 hours after treatment, in real-time. The BioTrace platform is designed to offer real-time visualization of the complete ablation zone in real-time. This is combined with smart, personalized tools for treatment planning and assessment, allowing physicians to provide optimal care for their patients. The platform utilizes standard imaging modalities such as ultrasound (US), computed tomography (CT), or magnetic resonance imaging (MRI).

BioTrace interfaces with commercial ultrasound imaging systems to monitor the tissue's unique "biological signature" as it responds to heat during thermal ablation. This signature is then used to predict and display the thermal effect 24 hours post-procedure in real-time, thereby enhancing the surgeon's control and accuracy during the operation, minimizing damage to healthy tissue, and maximizing the ablation of the target tissue. BioTrace is a comprehensive system that positively impacts and enhances all aspects of patient care, from pre-surgical planning, through planning & simulation, to real-time lesion imaging and efficacy analysis. Techsomed is presently conducting a field evaluation of its BioTraceIO360 software in conjunction with GE HealthCare’s (Chicago, IL, USA) LOGIQ E10 Series ultrasound imaging technology. The goal of this evaluation is to introduce an automated visualization and control solution for liver ablation procedures.

"By combining the outstanding image quality of the LOGIQ E10 with our BioTrace generative AI capabilities for personalized treatment and real time ablation zone visualization, we aim to offer a new level of treatment optimization and precision for the benefit of both patients and physicians," said Yossi Abu, CEO of TechsoMed. "We are very excited for this opportunity as this initiative marks a significant milestone in our commitment to advancing patient care and driving scientific progress in the ablation market worldwide."

Print article



view channel
Image: Physicians using the Zenition 90 Motorized mobile X-ray system (Photo courtesy of Royal Philips)

High-Powered Motorized Mobile C-Arm Delivers State-Of-The-Art Images for Challenging Procedures

During complex surgical procedures, clinicians depend on surgical imaging systems as they navigate challenging anatomy to quickly visualize small anatomical details while minimizing X-ray exposure.... Read more


view channel
Image: The device creates microbubbles that temporarily disrupt the BBB, permitting the entry of immunotherapy into the brain (Photo courtesy of Northwestern)

Ultrasound Technology Breaks Blood-Brain Barrier for Glioblastoma Treatment

Despite extensive molecular studies, the outlook for patients diagnosed with the aggressive brain cancer known as glioblastoma (GBM) continues to be poor. This is partly due to the blood-brain barrier... Read more

Nuclear Medicine

view channel
Image: 68Ga-NC-BCH whole-body PET imaging rapidly targets an important gastrointestinal cancer biomarker in lesions in GI cancer patients (Photo courtesy of Qi, Guo, et al.; doi.org/10.2967/jnumed.123.267110)

New PET Radiotracer Enables Same-Day Imaging of Key Gastrointestinal Cancer Biomarker

Gastrointestinal cancers rank among the most prevalent cancers worldwide, contributing to over a quarter of all cancer cases and over one-third of cancer-related deaths annually. The initial symptoms of... Read more

General/Advanced Imaging

view channel
Image: The denoised image is less noisy and the defect is more detectable and visually clearer with DEMIST (Photo courtesy of Abhinav Jha/WUSTL)

Artificial Intelligence Tool Enhances Usability of Medical Images

Doctors use myocardial perfusion imaging (MPI) single-photon emission computed tomography (SPECT) images to evaluate blood flow to the heart muscle. To capture these images, patients are administered a... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.